BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa

Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia. To fully appreciate this endeavour, BioStock reached out to Spago’s CEO Mats Hansen.

Read the interview with Mats Hansen at biostock.se:

Spago Nanomedical's promising cancer therapy approved for phase I/IIa - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/